Black Titan (NASDAQ:BTTC) Releases Quarterly Earnings Results

Black Titan (NASDAQ:BTTC) announced its earnings results on Friday. The company reported ($0.22) earnings per share for the quarter, FiscalAI reports.

Black Titan Trading Down 8.9%

BTTC stock opened at $0.90 on Friday. The business has a 50 day moving average of $1.22. The stock has a market cap of $9.67 million, a PE ratio of -0.30 and a beta of 1.20. Black Titan has a one year low of $0.86 and a one year high of $39.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC bought a new position in Black Titan in the fourth quarter valued at $26,000. HRT Financial LP purchased a new position in shares of Black Titan during the 4th quarter valued at about $28,000. Marex Group plc bought a new stake in Black Titan in the 4th quarter worth approximately $84,000. Finally, Armistice Capital LLC purchased a new stake in Black Titan in the fourth quarter worth approximately $840,000.

About Black Titan

Titan Pharmaceuticals, Inc is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.